MIK665

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Acute Myeloid Leukemia (AML)Multiple Myeloma (MM)Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), LymphomaNon-Hodgkin Lymphoma (NHL)

Phase 1

Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma

CompletedNCT02992483

Novartis PharmaceuticalsMultiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma

Start: 2017-07-12End: 2019-06-07Updated: 2021-08-03

VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)

TerminatedNCT04702425

Novartis PharmaceuticalsAcute Myeloid Leukemia (AML), Multiple Myeloma (MM), Non-Hodgkin Lymphoma (NHL)

Start: 2021-06-23End: 2024-07-23Updated: 2025-10-10

Related Papers

A First in Human Study of VOB560 in Combination with MIK665 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, or Multiple Myeloma

Blood2024-11-052 citations

Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients

Communications Medicine2023-10-2552 citations

Abstract 4482: S64315 (MIK665) is a potent and selective Mcl1 inhibitor with strong antitumor activity across a diverse range of hematologic tumor models

Cancer Research2019-07-0113 citations

Abstract 4477: MIK665/S64315, a novel Mcl-1 inhibitor, in combination with Bcl-2 inhibitors exhibits strong synergistic antitumor activity in a range of hematologic malignancies

Cancer Research2019-07-0111 citations

Abstract 4477: MIK665/S64315, a novel Mcl-1 inhibitor, in combination with Bcl-2 inhibitors exhibits strong synergistic antitumor activity in a range of hematologic malignancies

Experimental and Molecular Therapeutics2019-07-013 citations

Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.

2018-10-1120 citations